CureVac (NASDAQ:CVAC) Shares Gap Down – Here’s Why

CureVac N.V. (NASDAQ:CVAC) shares gapped down before the market opened on Friday . The stock had previously closed at $4.28, but opened at $4.15. CureVac shares last traded at $4.1550, with a volume of 546,855 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CureVac in a report on Tuesday. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CureVac presently has a consensus rating of “Hold” and an average price target of $6.83.

CureVac Stock Down 2.8%

The firm’s 50 day simple moving average is $5.20 and its 200 day simple moving average is $5.30. The company has a market cap of $933.25 million, a price-to-earnings ratio of 5.78 and a beta of 1.77. The company has a quick ratio of 3.69, a current ratio of 3.70 and a debt-to-equity ratio of 0.03.

CureVac (NASDAQ:CVAC) last issued its quarterly earnings data on Monday, November 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. CureVac had a negative return on equity of 23.03% and a net margin of 199.92%.The business had revenue of $63.53 million during the quarter, compared to the consensus estimate of $21.40 million. Sell-side analysts anticipate that CureVac N.V. will post 0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On CureVac

Institutional investors and hedge funds have recently bought and sold shares of the stock. Deutsche Bank AG raised its position in shares of CureVac by 35.9% during the 1st quarter. Deutsche Bank AG now owns 230,813 shares of the company’s stock worth $639,000 after buying an additional 60,941 shares in the last quarter. Nuveen LLC acquired a new position in shares of CureVac during the first quarter valued at approximately $232,000. State of Wyoming bought a new stake in CureVac during the first quarter worth approximately $317,000. Cubist Systematic Strategies LLC acquired a new stake in CureVac in the first quarter worth approximately $142,000. Finally, Integrated Wealth Concepts LLC boosted its stake in CureVac by 25.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after purchasing an additional 3,000 shares in the last quarter. Institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.